Ocular Therapeutix Misses Q3 2026 Estimates as Revenue Falls 11% to $12.9M

Ocular Therapeutix (OCUL) missed estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $12.9 million, down 11% from a year earlier, below the $14.3 million estimate, and adjusted EPS was -$0.42, down 14% from a year earlier, below the -$0.36 estimate.

Shares fell 0.8% in premarket trading as of 7:00 a.m. ET, to $6.54 from a $6.59 close.

Q3 2026 scorecard

By our calculation, revenue was $1.4 million below the estimate and adjusted EPS was $0.06 below it. The QoQ column compares with the previous quarter's revenue of $13.5 million and adjusted EPS of -$0.35. The YoY column compares with $14.5 million and -$0.37 in the same quarter a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 3 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 1 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $14.5 million, $13.3 million, $10.8 million, $13.5 million and $12.9 million.

What to watch

• Next-quarter estimates. Consensus calls for EPS of -$0.38 and revenue of $14.2 million next quarter, based on 5 analysts.
• Revenue growth. Whether revenue stabilizes after this quarter's 11% decline from a year earlier to $12.9 million.
• Estimate record. Whether Ocular Therapeutix returns to beating EPS estimates, which it did in 3 of its last 8 reports.
• Related coverage. See our reports on Barrick Mining, CNH Industrial, Constellation Energy and Target Hospitality.

Sources: Results are from Ocular Therapeutix's Nov. 9, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Ocular Therapeutix's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.